Try the modernized beta website. Learn more about the modernization effort.
Working… Menu

A Study of Brentuximab Vedotin Combined With Nivolumab for Relapsed or Refractory Hodgkin Lymphoma

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT02572167
Recruitment Status : Completed
First Posted : October 8, 2015
Results First Posted : March 7, 2019
Last Update Posted : November 5, 2021
Bristol-Myers Squibb
Information provided by (Responsible Party):
Seagen Inc.

Brief Summary:
The purpose of this study is to assess the safety profile and antitumor activity of brentuximab vedotin administered in combination with nivolumab in patients with relapsed or refractory Hodgkin lymphoma (HL)

Condition or disease Intervention/treatment Phase
Hodgkin Lymphoma Drug: brentuximab vedotin Drug: nivolumab Phase 1 Phase 2

Detailed Description:

This study will examine the safety profile and antitumor activity when brentuximab vedotin is combined with nivolumab. Patients will be treated for up to four 21-day cycles with brentuximab vedotin 1.8 mg/kg and nivolumab 3 mg/kg.

There will be 3 parts to this study. In Part 1, the safety of combination treatment will be evaluated by a Safety Monitoring Committee (SMC) prior to expansion of enrollment to evaluate treatment effect in Part 2. Part 2 of the study will further characterize the safety and antitumor activity of brentuximab vedotin combined with nivolumab by enrolling patients at the recommended dose schedule determined in Part 1. Part 3 of the study will evaluate the safety and antitumor activity of combination treatment administered at an alternate dosing schedule determined by cumulative safety and activity data from Parts 1 and 2.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 93 participants
Allocation: N/A
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Phase 1/2 Study Evaluating Brentuximab Vedotin in Combination With Nivolumab in Patients With Relapsed or Refractory Hodgkin Lymphoma After Failure of Frontline Therapy
Actual Study Start Date : October 31, 2015
Actual Primary Completion Date : March 1, 2018
Actual Study Completion Date : October 21, 2021

Arm Intervention/treatment
Experimental: Brentuximab Vedotin + Nivolumab
Brentuximab vedotin plus nivolumab
Drug: brentuximab vedotin
1.8 mg/kg by intravenous (IV) infusion for up to 4 cycles
Other Name: SGN-35, ADCETRIS

Drug: nivolumab
3 mg/kg by intravenous (IV) infusion for up to 4 cycles
Other Name: BMS-936558, OPDIVO

Primary Outcome Measures :
  1. Number of Participants With Adverse Events (AEs) [ Time Frame: Up to 28.9 months ]
    Treatment-emergent adverse events (TEAEs) are presented and defined as newly occurring (not present at baseline) or worsening after first dose of investigational product. The timeframe includes a 6.01 safety reporting period and additional long-term follow up through 28.9 months.

  2. Complete Remission Rate [ Time Frame: Up to 3.42 months ]
    Number of patients with complete metabolic response (CMR) at end of treatment

Secondary Outcome Measures :
  1. Objective Response Rate [ Time Frame: Up to 3.42 months ]
    Number of patients with complete metabolic response (CMR) or partial metabolic response (PMR)

  2. Duration of Complete Response [ Time Frame: Up to approximately 3 years ]
  3. Duration of Objective Response [ Time Frame: Up to approximately 3 years ]
  4. Progression-free Survival Post-autologous Stem Cell Transplant [ Time Frame: Up to approximately 3 years ]
    PFS is defined as the time from the start of study treatment to the first documentation of disease progression or to death, whichever comes first.

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Relapsed or refractory Hodgkin lymphoma following failure of standard frontline chemotherapy for the treatment of classical Hodgkin lymphoma
  • Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1

Exclusion Criteria:

  • Previously treated with brentuximab vedotin, immune-oncology agents, or received an allogeneic or autologous stem cell transplant
  • Documented history of a cerebral vascular event
  • History of another invasive malignancy that has not been in remission for at least 3 years
  • History of progressive multifocal leukoencephalopathy (PML)

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT02572167

Layout table for location information
United States, California
City of Hope National Medical Center
Duarte, California, United States, 91010-3000
Stanford Cancer Center
Stanford, California, United States, 94305
United States, Massachusetts
Dana Farber Cancer Institute
Boston, Massachusetts, United States, 02215
United States, Michigan
Karmanos Cancer Institute / Wayne State University
Detroit, Michigan, United States, 48201
United States, Minnesota
Mayo Clinic Minnesota
Rochester, Minnesota, United States, 55905
United States, Missouri
Washington University School of Medicine
Saint Louis, Missouri, United States, 63110
United States, Nebraska
University of Nebraska Medical Center
Omaha, Nebraska, United States, 68198-7680
United States, New Jersey
Hackensack University Medical Center
Hackensack, New Jersey, United States, 07601
United States, New York
Memorial Sloan Kettering Cancer Center - Commack
Commack, New York, United States, 11725
Memorial Sloan Kettering Cancer Center
New York, New York, United States, 10021
United States, North Carolina
Duke University Medical Center
Durham, North Carolina, United States, 27710
United States, Ohio
James Cancer Hospital / Ohio State University
Columbus, Ohio, United States, 43210
United States, Texas
Charles A. Sammons Cancer Center / Baylor University Medical Center
Dallas, Texas, United States, 75246
Sponsors and Collaborators
Seagen Inc.
Bristol-Myers Squibb
Layout table for investigator information
Study Director: Faith Galderisi, DO Seagen Inc.
  Study Documents (Full-Text)

Documents provided by Seagen Inc.:
Study Protocol  [PDF] January 23, 2017
Statistical Analysis Plan  [PDF] August 9, 2017

Publications of Results:
Publications automatically indexed to this study by Identifier (NCT Number):
Layout table for additonal information
Responsible Party: Seagen Inc. Identifier: NCT02572167    
Other Study ID Numbers: SGN35-025
First Posted: October 8, 2015    Key Record Dates
Results First Posted: March 7, 2019
Last Update Posted: November 5, 2021
Last Verified: November 2021
Keywords provided by Seagen Inc.:
Monomethyl auristatin E
Antigens, CD30
Antibody-Drug Conjugate
Antibodies, Monoclonal
Autologous stem cell transplant
Additional relevant MeSH terms:
Layout table for MeSH terms
Hodgkin Disease
Neoplasms by Histologic Type
Lymphoproliferative Disorders
Lymphatic Diseases
Immunoproliferative Disorders
Immune System Diseases
Brentuximab Vedotin
Antineoplastic Agents, Immunological
Antineoplastic Agents
Immune Checkpoint Inhibitors
Molecular Mechanisms of Pharmacological Action